Loss of Heterozygosity on Chromosomes 11 and 17 Are Markers of Recurrence in TCC of the Bladder
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Wo 2010/075007 A2
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 1 July 2010 (01.07.2010) WO 2010/075007 A2 (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C12Q 1/68 (2006.01) G06F 19/00 (2006.01) kind of national protection available): AE, AG, AL, AM, C12N 15/12 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, (21) International Application Number: DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/US2009/067757 HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, (22) International Filing Date: KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, 11 December 2009 ( 11.12.2009) ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, (25) Filing Language: English SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, (26) Publication Language: English TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 12/3 16,877 16 December 2008 (16.12.2008) US kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, (71) Applicant (for all designated States except US): DODDS, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, W., Jean [US/US]; 938 Stanford Street, Santa Monica, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, CA 90403 (US). -
Searching the Genomes of Inbred Mouse Strains for Incompatibilities That Reproductively Isolate Their Wild Relatives
Journal of Heredity 2007:98(2):115–122 ª The American Genetic Association. 2007. All rights reserved. doi:10.1093/jhered/esl064 For permissions, please email: [email protected]. Advance Access publication January 5, 2007 Searching the Genomes of Inbred Mouse Strains for Incompatibilities That Reproductively Isolate Their Wild Relatives BRET A. PAYSEUR AND MICHAEL PLACE From the Laboratory of Genetics, University of Wisconsin, Madison, WI 53706. Address correspondence to the author at the address above, or e-mail: [email protected]. Abstract Identification of the genes that underlie reproductive isolation provides important insights into the process of speciation. According to the Dobzhansky–Muller model, these genes suffer disrupted interactions in hybrids due to independent di- vergence in separate populations. In hybrid populations, natural selection acts to remove the deleterious heterospecific com- binations that cause these functional disruptions. When selection is strong, this process can maintain multilocus associations, primarily between conspecific alleles, providing a signature that can be used to locate incompatibilities. We applied this logic to populations of house mice that were formed by hybridization involving two species that show partial reproductive isolation, Mus domesticus and Mus musculus. Using molecular markers likely to be informative about species ancestry, we scanned the genomes of 1) classical inbred strains and 2) recombinant inbred lines for pairs of loci that showed extreme linkage disequi- libria. By using the same set of markers, we identified a list of locus pairs that displayed similar patterns in both scans. These genomic regions may contain genes that contribute to reproductive isolation between M. domesticus and M. -
Laboratory Testing for Her2 Status in Breast Cancer
Laboratory Testing for Her2 Status in Breast Cancer Katherine Geiersbach, M.D. Assistant Professor, Department of Pathology May 28, 2015 Overview • Clinical relevance of Her2 status for treatment of breast cancer • Standard approaches for determining Her2 status in breast cancer • Current concepts and controversies in Her2 testing 2 Who gets breast cancer? • Breast cancer is one of the most common malignancies to affect women • About 1 in 8 women will be diagnosed with breast cancer at some point in her lifetime • Most cases of breast cancer are sporadic, but a small percentage (5-10%) are related to a heritable gene mutation, most commonly BRCA1 or BRCA2 • Having a first degree relative with breast cancer increases a woman’s chance of developing breast cancer • Screening mammography is recommended for older women – US Preventive Services Task Force: Every 2 years starting at age 50 – American Cancer Society, others: Every 2 years starting at age 40 How is breast cancer treated? • Surgery: excision with or without sentinel lymph node biopsy – Breast conserving: lumpectomy, partial mastectomy – Mastectomy • Chemotherapy: before and/or after surgery • Radiation • Targeted therapies – Hormone therapy: Tamoxifen, aromatase inhibitors – Her2 targeted therapy for cancers with overexpression of the gene ERBB2, commonly called Her2 or Her2/neu • Treatment is based on testing for ER, PR, and Her2 status, as well as cancer grade and stage. 4 Her2 targeted therapy • Herceptin (trastuzumab) • Others: pertuzumab (Perjeta), T-DM1 (Kadcyla), and lapatinib (Tykerb) • Recent data shows that a combination of pertuzumab, trastuzumab, and docetaxel (PTD) improved progression free survival compared to patients who had only trastuzumab and docetaxel (TD)1,2 source: http://www.perjeta.com/hcp/moa 1. -
(12) Patent Application Publication (10) Pub. No.: US 2006/0088532 A1 Alitalo Et Al
US 20060O88532A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0088532 A1 Alitalo et al. (43) Pub. Date: Apr. 27, 2006 (54) LYMPHATIC AND BLOOD ENDOTHELIAL Related U.S. Application Data CELL GENES (60) Provisional application No. 60/363,019, filed on Mar. (76) Inventors: Kari Alitalo, Helsinki (FI); Taija 7, 2002. Makinen, Helsinki (FI); Tatiana Petrova, Helsinki (FI); Pipsa Publication Classification Saharinen, Helsinki (FI); Juha Saharinen, Helsinki (FI) (51) Int. Cl. A6IR 48/00 (2006.01) Correspondence Address: A 6LX 39/395 (2006.01) MARSHALL, GERSTEIN & BORUN LLP A6II 38/18 (2006.01) 233 S. WACKER DRIVE, SUITE 6300 (52) U.S. Cl. .............................. 424/145.1: 514/2: 514/44 SEARS TOWER (57) ABSTRACT CHICAGO, IL 60606 (US) The invention provides polynucleotides and genes that are (21) Appl. No.: 10/505,928 differentially expressed in lymphatic versus blood vascular endothelial cells. These genes are useful for treating diseases (22) PCT Filed: Mar. 7, 2003 involving lymphatic vessels, such as lymphedema, various inflammatory diseases, and cancer metastasis via the lym (86). PCT No.: PCT/USO3FO6900 phatic system. Patent Application Publication Apr. 27, 2006 Sheet 1 of 2 US 2006/0088532 A1 integrin O9 integrin O1 KIAAO711 KAAO644 ApoD Fig. 1 Patent Application Publication Apr. 27, 2006 Sheet 2 of 2 US 2006/0088532 A1 CN g uueleo-gº US 2006/0O88532 A1 Apr. 27, 2006 LYMPHATIC AND BLOOD ENDOTHELLAL CELL lymphatic vessels, such as lymphangiomas or lymphang GENES iectasis. Witte, et al., Regulation of Angiogenesis (eds. Goldber, I. D. & Rosen, E. M.) 65-112 (Birkauser, Basel, BACKGROUND OF THE INVENTION Switzerland, 1997). -
Hormonal Regulation of TSEI-Repressed Genes:Evidence
MOLECULAR AND CELLULAR BIOLOGY, JUlY 1989, p. 2837-2846 Vol. 9, No. 7 0270-7306/89/072837-10$02.00/0 Copyright C) 1989, American Society for Microbiology Hormonal Regulation of TSEI-Repressed Genes: Evidence for Multiple Genetic Controls in Extinction MATHEW J. THAYER AND R. E. K. FOURNIER* Department of Molecul(ar Medicine, Fred Hiutchinson Cancer Research Center, 1124 Columbia Street, Seattle, Washington 98104 Received 9 January 1989/Accepted 26 March 1989 Somatic cell hybrids formed by fusing hepatoma cells with fibroblasts generally fail to express liver functions, a phenomenon termed extinction. Previous studies demonstrated that extinction of the genes encoding tyrosine aminotransferase, phosphoenolpyruvate carboxykinase, and argininosuccinate synthetase is mediated by a specific genetic locus (TSEI) that maps to mouse chromosome 11 and human chromosome 17. In this report, we show that full repression of these genes requires a genetic factor in addition to TSE1. This conclusion is based on the observation that residual gene activity was apparent in monochromosomal hybrids retaining human TSEI but not in complex hybrids retaining many fibroblast chromosomes. Furthermore, TSE1- repressed genes were hormone inducible, whereas fully extinguished genes were not. Analysis of hybrid segregants indicated that genetic loci required for the complete repression phenotype were distinct from TSE1. Tissue-specific gene expression in mammalian cells is ing that single fibroblast chromosome are extinguished for primarily regulated at the level of transcription (8). A par- both serum albumin and alcohol dehydrogenase gene activ- ticular gene may account for a large fraction of total tran- ity (A. C. Chin and R. E. K. Fournier, submitted for publi- scription in one cell type yet be virtually silent in other cell cation). -
134 Mb (Almost the Same As the Size of Chromosome 10). It Is ~4–4.5% of the Total Human Genome
Chromosome 11 ©Chromosome Disorder Outreach Inc. (CDO) Technical genetic content provided by Dr. Iosif Lurie, M.D. Ph.D Medical Geneticist and CDO Medical Consultant/Advisor. Ideogram courtesy of the University of Washington Department of Pathology: ©1994 David Adler.hum_11.gif Introduction The genetic size of chromosome 11 is ~134 Mb (almost the same as the size of chromosome 10). It is ~4–4.5% of the total human genome. The length of its short arm is ~50 Mb; the length of its long arm in ~84 Mb. Chromosome 11 is a very gene–rich area. It contains ~1,500 genes. Mutations of ~200 of these genes are known to cause birth defects or some functional abnormalities. The short arm of chromosome 11 contains a region which is known to be imprinted. As a result duplications of this region will have different manifestations depending on the sex of the parent responsible for this defect. Phenotypes of persons with duplications of the maternal origin will be different from the phenotypes of the persons with a paternal duplication of the same area. There are ~1,400 patients with different structural abnormalities of chromosome 11 as the only abnormality or in association with abnormalities for other chromosomes. At least 800 of these patients had different deletions of chromosome 11. Deletions of the short arm have been reported in ~250 patients (including those with an additional imbalance); deletions of the long arm have been described in ~550 patients. There are two syndromes caused by deletions of the short arm (both of these syndromes have been known for several years) and one well–known syndrome caused by distal deletions of the long arm (Jacobsen syndrome). -
The KMT1A-GATA3-STAT3 Circuit Is a Novel Self-Renewal Signaling of Human Bladder Cancer Stem Cells Zhao Yang1, Luyun He2,3, Kais
The KMT1A-GATA3-STAT3 circuit is a novel self-renewal signaling of human bladder cancer stem cells Zhao Yang1, Luyun He2,3, Kaisu Lin4, Yun Zhang1, Aihua Deng1, Yong Liang1, Chong Li2, 5, & Tingyi Wen1, 6, 1CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China 2Core Facility for Protein Research, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, China 3CAS Key Laboratory of Infection and Immunity, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, China 4Department of Oncology, the Second Affiliated Hospital of Soochow University, Suzhou 215000, China 5Beijing Jianlan Institute of Medicine, Beijing 100190, China 6Savaid Medical School, University of Chinese Academy of Sciences, Beijing 100049, China Correspondence author: Tingyi Wen, e-mail: [email protected] Chong Li, e-mail: [email protected] Supplementary Figure S1. Isolation of human bladder cancer stem cells. BCMab1 and CD44 were used to isolate bladder cancer stem cells (BCSCs: BCMab1+CD44+) and bladder cancer non-stem cells (BCNSCs: BCMab1-CD44-) from EJ, samples #1 and #2 by flow cytometry. Supplementary Figure S2. Gene ontology analysis of downregulated genes of human BCSCs. (A) Pathway enrichment of 103 downregulated genes in BCSCs. (B) The seven downregulated genes in BCSCs participating in centromeric heterochromatin, mRNA-3’-UTR binding and translation regulator activity signaling pathways were validated by qRT-PCR. Data are presented as mean ± SD. P < 0.05; P < 0.01. Supplementary Figure S3. The expression of KMT1A is higher in human BC than that in peri-tumor tissues. (A) The expression of KMT1A was higher in BC samples than that in peri-tumors as assessed by immunohistochemistry, Scale bar = 50 m. -
Rabbit Anti-Human TK1 Polyclonal Antibody (CABT-L2019) This Product Is for Research Use Only and Is Not Intended for Diagnostic Use
Rabbit Anti-Human TK1 Polyclonal Antibody (CABT-L2019) This product is for research use only and is not intended for diagnostic use. PRODUCT INFORMATION Product Overview Polyclonal Antibody to Thymidine Kinase 1, Soluble (Knockout Validated) Specificity The antibody is a rabbit polyclonal antibody raised against TK1. It has been selected for its ability to recognize TK1 in immunohistochemical staining and western blotting. Target TK1 Immunogen Recombinant fragment corresponding to human TK1 (Ser2~Asn234) Isotype IgG Source/Host Rabbit Species Reactivity Human Purification Antigen-specific affinity chromatography followed by Protein A affinity chromatography Conjugate Unconjugated Applications WB Format Liquid Concentration Lot specific Size 200 μg Buffer Supplied as solution form in 0.01M PBS with 50% glycerol, pH7.4. Preservative 0.05% Proclin-300 Storage Avoid repeated freeze/thaw cycles. Store at 4°C for frequent use. Aliquot and store at -20°C for 12 months. Ship 4°C with ice bags Warnings For research use only. BACKGROUND 45-1 Ramsey Road, Shirley, NY 11967, USA Email: [email protected] Tel: 1-631-624-4882 Fax: 1-631-938-8221 1 © Creative Diagnostics All Rights Reserved Introduction TK1 Belongs to the thymidine kinase family. Keywords TK2;Thymidine kinase, cytosolic GENE INFORMATION Gene Name TK1 thymidine kinase 1, soluble [ Homo sapiens (human) ] Official Symbol TK1 Synonyms TK1; thymidine kinase 1, soluble; TK2; thymidine kinase, cytosolic; thymidine kinase-1; thymidine kinase 1 soluble isoform; Entrez Gene ID 7083 -
Duplications of 17P FTNW
Duplications of 17p rarechromo.org 17p duplications A 17p duplication means that the cells of the body have a small but variable amount of extra genetic material from one of their 46 chromosomes – chromosome 17. For healthy development, chromosomes should contain just the right amount of genetic material (DNA) – not too much and not too little. Like most other chromosome disorders, having an extra part of chromosome 17 may increase the risk of birth defects, developmental delay and learning (intellectual) disability. However, the problems vary and depend on what and how much genetic material is duplicated. Background on Chromosomes Chromosomes are structures which contain our DNA and are found in almost every cell of the body. Every chromosome contains thousands of genes which may be thought of as individual instruction booklets (or recipes) that contain all the genetic information telling the body how to develop, grow and function. Chromosomes (and genes) usually come in pairs with one member of each chromosome pair being inherited from each parent. Most cells of the human body have a total of 46 (23 pairs of) chromosomes. The egg and the sperm cells, however have 23 unpaired chromosomes, so that when the egg and sperm join together at conception, the chromosomes pair up and the number is restored to 46. Of these 46 chromosomes, two are the sex chromosomes that determine gender. Females have two X chromosomes and males have one X chromosome and one Y chromosome. The remaining 44 chromosomes are grouped in 22 pairs, numbered 1 to 22 approximately from the largest to the smallest. -
Evidence for Linkage of Regions on Chromosomes 6 and 11 to Plasma Glucose Concentrations in Mexican Americans Michael P
Downloaded from genome.cshlp.org on September 26, 2021 - Published by Cold Spring Harbor Laboratory Press RESEARCH Evidence for Linkage of Regions on Chromosomes 6 and 11 to Plasma Glucose Concentrations in Mexican Americans Michael P. Stern, 1'4 Ravindranath Duggirala, 1 Braxton D. Mitchell, 2 Laurie J. Reinhart, ~ Sailaja Shivakumar, ~ Patricia A. Shipman, 3 Olga C. Uresandi, 3 Edgardo Benavides, 3 John Blangero, 2 and Peter O'Connell 3 1Division of Clinical Epidemiology, Department of Medicine, and 3Department of Pathology, University of Texas Health Science Center, San Antonio, Texas 78284; 2Department of Genetics, Southwest Foundation for Biomedical Research, San Antonio, Texas 78245 The genetic factors involved in type I1 diabetes are still unknown. To address this problem, we are creating a I0 to 15; cM genetic map on 444 individuals from 32 Mexican American families ascertained on a type !I diabetic proband. Using highly polymorphic microsatellite markers and a multipoint variance components method, we found evidence for linkage of plasma glucose concentration 2 hr after oral glucose administration to two regions on chromosome I1: Ig-hemoglobin (HBB} and markers DllS899/DIISI324 near the sulfonylurea receptor (SUR) gene. lod scores at these two loci were 2.77 and 3.37, respectively. The SUR gene region accounted for 4-4.7% of the phenotypic variance. Evidence for linkage to fasting glucose concentration was also observed for two loci on chromosome 6, one of which is identical to a proposed susceptibility locus for type I diabetes {D6S290). When diabetics were excluded from the analyses, all lod scores became zero, suggesting that the observed linkages were with the trait diabetes rather than with normal variation in glucose levels. -
Application of Microarray-Based Comparative Genomic Hybridization in Prenatal and Postnatal Settings: Three Case Reports
SAGE-Hindawi Access to Research Genetics Research International Volume 2011, Article ID 976398, 9 pages doi:10.4061/2011/976398 Case Report Application of Microarray-Based Comparative Genomic Hybridization in Prenatal and Postnatal Settings: Three Case Reports Jing Liu, Francois Bernier, Julie Lauzon, R. Brian Lowry, and Judy Chernos Department of Medical Genetics, University of Calgary, 2888 Shaganappi Trail NW, Calgary, AB, Canada T3B 6A8 Correspondence should be addressed to Judy Chernos, [email protected] Received 16 February 2011; Revised 20 April 2011; Accepted 20 May 2011 Academic Editor: Reha Toydemir Copyright © 2011 Jing Liu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Microarray-based comparative genomic hybridization (array CGH) is a newly emerged molecular cytogenetic technique for rapid evaluation of the entire genome with sub-megabase resolution. It allows for the comprehensive investigation of thousands and millions of genomic loci at once and therefore enables the efficient detection of DNA copy number variations (a.k.a, cryptic genomic imbalances). The development and the clinical application of array CGH have revolutionized the diagnostic process in patients and has provided a clue to many unidentified or unexplained diseases which are suspected to have a genetic cause. In this paper, we present three clinical cases in both prenatal and postnatal settings. Among all, array CGH played a major discovery role to reveal the cryptic and/or complex nature of chromosome arrangements. By identifying the genetic causes responsible for the clinical observation in patients, array CGH has provided accurate diagnosis and appropriate clinical management in a timely and efficient manner. -
Non-Random X-Chromosome Inactivation in Mouse X-Autosome Translocation Embryos—Location of the Inactivation Centre
J. Embryol. exp. Morph. 78, 1-22 (1983) Printed in Great Britain (E) The Company of Biologists Limited 1983 Non-random X-chromosome inactivation in mouse X-autosome translocation embryos—location of the inactivation centre By SOHAILA RASTAN1 From the Division of Comparative Medicine, Clinical Research Centre, Harrow SUMMARY X-chromosome inactivation was investigated cytologically using the modified Katida method which differentially stains inactive X-chromosome material at metaphase in balanced 13|-day female embryos heterozygous for four X-autosome rearrangements, reciprocal trans- locations T(X;4)37H, T(X;11)38H and T(X;16)16H (Searle's translocation) and the insertion translocation Is(7;X)lCt (Cattanach's translocation). In all cases non-random inactivation was found. In the reciprocal translocation heterozygotes only one translocation product ever showed Kanda staining. In addition in a proportion of cells from T(X;4)37H, T(X;11)38H &nd Is(7;X)lCt the Kanda staining revealed differential staining of X-chromosome material and attached autosomal material within the translocation product. In a study of 8£-day female embryos doubly heterozygous for Searle's translocation and Cattanach's translocation two unbalanced types of embryo were found. In one type of unbalanced female embryo of the karyotype 40(X(7)/X16;16/16) no inactivated X- chromosomal material is found. A second unbalanced type of female embryo, of the presump- tive karyotype 40(X(7)/XN;16x/l6) was found in which two inactivated chromosomes were present in the majority of metaphase spreads. A simple model for the initiation of X- chromosome inactivation based on the presence of a single inactivation centre distal to the breakpoint in Searle's translocation explains these findings.